When is Zepbound typically denied?
Zepbound is Eli Lilly's tirzepatide formulation indicated for chronic weight management in adults with obesity or overweight with comorbidities, and moderate-to-severe obstructive sleep apnea in adults with obesity. Insurance denials are common — particularly for plans that restrict GLP-1s to specific diagnoses or require step therapy. Knowing the exact denial reason on your Explanation of Benefits (EOB) is the first step toward a successful appeal.
Common denial reasons & how to counter them
Plan excludes weight-loss medications
If you have moderate-to-severe OSA documented by a sleep study, appeal under the OSA indication — Zepbound is FDA-approved for this and is not subject to weight-loss exclusions on most plans.
Prior auth requires Wegovy trial first
Document any prior Wegovy trial (dose, duration, response, side effects) or contraindication. If never tried, your prescriber can request an exception based on superior tirzepatide efficacy data.
BMI below plan threshold
Confirm BMI is documented at the most recent visit. Include all weight-related comorbidities — many plans accept BMI ≥ 27 with one comorbidity.
Quantity limit on higher doses
Submit a quantity-limit exception when titrating from 5 mg to 10 mg or 15 mg, with documented response and tolerability.
Documentation checklist
Strong appeals are built on documentation. Ask your prescriber's office to include each of the following in the appeal packet:
- Most recent BMI with date of measurement
- ICD-10 codes for obesity and all comorbidities (E66.x, G47.33 for OSA)
- Sleep study results (AHI) if appealing under the OSA indication
- Prior weight-management or GLP-1 therapy trials
- Letter of medical necessity from the prescriber
- Relevant labs (A1c, lipid panel)
- Copy of the original denial letter / EOB
Sample appeal letter for Zepbound
Copy the letter below into your appeal and have your prescriber personalize the clinical details. Always attach supporting chart notes and lab results.
[Date] [Insurance Plan Name] Attn: Appeals Department [Address] Re: Appeal of Denial — Zepbound (tirzepatide) Member: [Patient Name] Member ID: [ID] Claim/Reference #: [from denial letter] To the Appeals Reviewer: I am writing to appeal the denial of Zepbound (tirzepatide) issued on [denial date]. The stated reason was: "[exact reason from EOB]." [Patient] is a [age]-year-old [sex] with a BMI of [BMI] and the following weight-related comorbidities: [list — e.g., obstructive sleep apnea (AHI [value]), hypertension, dyslipidemia, prediabetes]. [If OSA: Patient has moderate-to-severe OSA documented by polysomnography on [date].] Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity, and for moderate-to-severe obstructive sleep apnea in adults with obesity. [Patient] meets the labeled indication based on the enclosed documentation. [Patient] has attempted lifestyle modification (documented [dates]) and prior therapies including [list]. Continued untreated [obesity/OSA] in this patient carries significant medical risk. Tirzepatide's dual GIP/GLP-1 receptor agonism has demonstrated superior weight reduction in head-to-head data versus monotherapy GLP-1s. Enclosed: chart notes, BMI documentation, [OSA study results if applicable], prior therapy trials, letter of medical necessity, and the original denial letter. I respectfully request that this denial be overturned. Sincerely, [Prescriber Name, Credentials] [Practice / NPI]
FAQ
Get a Zepbound approval-likelihood score
Answer a few clinical questions and receive a personalized assessment of your approval odds, plus a prior-authorization checklist tailored to your plan.
Educational guidance only — not medical or legal advice.